Insider Selling: Phreesia (NYSE:PHR) Insider Sells $50,401.20 in Stock

Key Points

• Insider David Linetsky sold 2,165 shares of Phreesia stock for $50,401.20, representing a 1.22% decrease in his ownership of the company.
• Phreesia reported a 14.9% increase in revenue year-over-year, with quarterly earnings surpassing analyst expectations at $0.01 EPS.
• Institutional investors continue to show interest in Phreesia, with 92.10% of the stock currently owned by such investors, indicating strong institutional confidence.

Phreesia, Inc. (NYSE:PHR - Get Free Report) insider David Linetsky sold 2,165 shares of the business's stock in a transaction on Tuesday, September 16th. The stock was sold at an average price of $23.28, for a total transaction of $50,401.20. Following the transaction, the insider owned 174,952 shares in the company, valued at approximately $4,072,882.56. The trade was a 1.22% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

David Linetsky also recently made the following trade(s):

• On Thursday, September 18th, David Linetsky sold 93 shares of Phreesia stock. The shares were sold at an average price of $23.94, for a total transaction of $2,226.42.
• On Wednesday, September 17th, David Linetsky sold 1,064 shares of Phreesia stock. The stock was sold at an average price of $23.50, for a total transaction of $25,004.00.
• On Friday, August 22nd, David Linetsky sold 17,445 shares of Phreesia stock. The shares were sold at an average price of $29.73, for a total transaction of $518,639.85.
• On Monday, August 18th, David Linetsky sold 78 shares of Phreesia stock. The stock was sold at an average price of $29.16, for a total value of $2,274.48.
• On Thursday, July 17th, David Linetsky sold 2,063 shares of Phreesia stock. The shares were sold at an average price of $26.89, for a total value of $55,474.07.
• On Friday, June 27th, David Linetsky sold 23,729 shares of Phreesia stock. The shares were sold at an average price of $28.50, for a total value of $676,276.50.

Phreesia Stock Performance

Shares of PHR stock traded up $0.87 during trading on Monday, reaching $24.74. 1,065,169 shares of the company's stock were exchanged, compared to its average volume of 1,230,749. Phreesia, Inc. has a twelve month low of $17.07 and a twelve month high of $32.76. The firm's fifty day moving average price is $27.51 and its 200-day moving average price is $26.40. The company has a quick ratio of 2.12, a current ratio of 2.12 and a debt-to-equity ratio of 0.02. The stock has a market capitalization of $1.48 billion, a PE ratio of -58.90 and a beta of 0.72.

Phreesia (NYSE:PHR - Get Free Report) last announced its quarterly earnings results on Thursday, September 4th. The company reported $0.01 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.07) by $0.08. Phreesia had a negative return on equity of 8.75% and a negative net margin of 5.35%.The business had revenue of $117.26 million during the quarter, compared to the consensus estimate of $116.39 million. During the same quarter last year, the firm posted ($0.03) EPS. The company's quarterly revenue was up 14.9% on a year-over-year basis. Phreesia has set its FY 2026 guidance at EPS. As a group, sell-side analysts anticipate that Phreesia, Inc. will post -1.1 EPS for the current year.

Analyst Ratings Changes

A number of research analysts recently commented on PHR shares. JMP Securities upped their price target on shares of Phreesia from $30.00 to $34.00 and gave the company a "market outperform" rating in a research note on Monday, September 8th. Mizuho started coverage on Phreesia in a research report on Wednesday, August 27th. They issued an "outperform" rating and a $36.00 target price on the stock. Canaccord Genuity Group lifted their price target on Phreesia from $34.00 to $38.00 and gave the stock a "buy" rating in a report on Friday, September 5th. Piper Sandler upped their price objective on Phreesia from $33.00 to $34.00 and gave the company an "overweight" rating in a report on Friday, September 5th. Finally, Needham & Company LLC increased their price objective on Phreesia from $29.00 to $35.00 and gave the stock a "buy" rating in a research report on Friday, September 5th. One analyst has rated the stock with a Strong Buy rating and twelve have assigned a Buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus price target of $34.08.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Cubist Systematic Strategies LLC acquired a new stake in Phreesia during the first quarter worth about $774,000. Principal Financial Group Inc. acquired a new stake in shares of Phreesia in the 1st quarter valued at approximately $1,623,000. Deutsche Bank AG increased its position in Phreesia by 95.9% during the 4th quarter. Deutsche Bank AG now owns 57,297 shares of the company's stock worth $1,442,000 after purchasing an additional 28,047 shares in the last quarter. Acadian Asset Management LLC lifted its stake in Phreesia by 105.2% in the 1st quarter. Acadian Asset Management LLC now owns 225,317 shares of the company's stock valued at $5,754,000 after purchasing an additional 115,527 shares during the last quarter. Finally, Bessemer Group Inc. boosted its position in Phreesia by 23.2% in the first quarter. Bessemer Group Inc. now owns 47,758 shares of the company's stock valued at $1,222,000 after buying an additional 8,978 shares in the last quarter. Institutional investors and hedge funds own 92.10% of the company's stock.

About Phreesia

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.